Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history

References

• Godman B, Bennie M, Baumgärtel C, et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmecon Health Econ Ther Pathw 2012;13(Suppl 3):5-20
   Google Scholar
• OECD (2011), “Pharmaceutical expenditure”, in OECD, Health at a Glance 2011: OECD Indicators, OECD Publishing. Available from: www.oecd.org/els/health-systems/49105858.pdf [Last accessed December 2013]
   Google Scholar
• Garattini S, Bertele V, Godman B, et al. Enhancing the rational use of new medicines across European healthcare systems – A Position Paper. Eur J Clin Pharmacol 2008;64:1137-8
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol 2014;5:106
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Hoffman M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev Pharmacoecon Outcomes Res 2009;9:65-83
   PubMedGoogle Scholar
• Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 2010;10:707-22
   PubMed Web of Science ®Google Scholar
• Vončina L, Strizrep T, Godman B, et al. Influence of demand-side measures to enhance renin–angiotensin prescribing efficiency in Europe: implications for the future. Expert Rev Pharmacoecon Outcomes Res 2011;11:469-79
   PubMed Web of Science ®Google Scholar
• Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012;12:125-30
   PubMed Web of Science ®Google Scholar
• van Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of PPIs and statins in the Netherlands; influence and future implications. J Comp Eff Res 2012;1:527-38
   PubMed Web of Science ®Google Scholar
• Sakshaug S, Furu K, Karlstad O, et al. Switching statins in Norway after new reimbursement policy – a nationwide prescription study. Br J Clin Pharmacol 2007;64:476-81
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Miranda J, et al. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. Int J Clin Pract 2013;67:853-62
   PubMed Web of Science ®Google Scholar
• Hesse U, Godman B, Petzold M, et al. Impact of delisting ARBs, apart from losartan, on ARB utilisation patterns in Denmark: implications for other countries. Appl Health Econ Health Policy 2013;11:677-85
   PubMedGoogle Scholar
• Martikainen J, Saastamoinen L, Korhonen M, et al. Impact of restricted reimbursement on the use of statins in Finland – A register-based study. Med Care 2010;48:761-6
   PubMed Web of Science ®Google Scholar
• Fraeyman J, Van Hal G, De Loof H, et al. Potential impact of policy regulation and generic competition on sales of cholesterol lowering medication, antidepressants and acid blocking agents in Belgium. Acta Clin Belg 2012;67(3):160-71
   PubMed Web of Science ®Google Scholar
• Moon J, Flett A, Godman B, et al. Getting better value from the NHS drug budget. BMJ 2011;342:30-2
   Google Scholar
• Martin A, Godman B, Miranda J, et al. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. J Comp Eff Res 2014;3(1):41-51
   PubMed Web of Science ®Google Scholar
• Norman C, Zarrinkoub R, Hasselström J, et al. Potential savings without compromising the quality of care. Int J Clin Pract 2009;63:1320-6
   PubMed Web of Science ®Google Scholar
• Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62:480-4
   PubMed Web of Science ®Google Scholar
• Wettermark B, Person A, Juhasz-Haverinen M, et al. Financial incentives linked to self-assessment of prescribing patterns – a new approach for quality improvement of drug prescribing in primary care. Qual Prim Care 2009;17:179-89
   PubMedGoogle Scholar
• Gustafsson LL, Wettermark B, Godman B, et al. The “Wise List”- A comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol 2011;108:224-33
   PubMed Web of Science ®Google Scholar
• Kaplan WA, Ritz LS, Vitello M, Wirtz VJ. Policies to promote use of generic medicines in low and middle income countries: a review of published literature. 2000–2010. Health Policy 2012;106(3):211-24
   PubMed Web of Science ®Google Scholar
• Cameron A, Mantel-Teeuwisse AK, Leufkens HGM, Laing RO. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health 2012;15(5):664-73
   PubMed Web of Science ®Google Scholar
• Zeng W. A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China. BMC Health Serv Res 2013;13:390
   PubMed Web of Science ®Google Scholar
• Lu C, Ross-Degnan D, Stephens P, et al. Changes in use of antidiabetic medications following price regulations in China (1999–2009. J Pharm Health Service Res 2013;4:3-11
   Google Scholar
• Li X, Zhang W. The impacts of health insurance on health care utilization among the older people in China. Soc Sci Med 2013;85:59-65
   PubMed Web of Science ®Google Scholar
• Meng Q, Xu L, Zhang Y, et al. Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet 2012;379(9818):805-14
   PubMed Web of Science ®Google Scholar
• Barber S, Huang B, Santoso B, et al. The reform of the essential medicines system in China: a comprehensive approach to universal coverage. J Glob Health 2013;3(1):010303
   Web of Science ®Google Scholar
• Sun J. International experiences of promoting generics use and its implications to China. J Evid Based Med 2013;6:74-80
   PubMedGoogle Scholar
• Li L. The challenges of healthcare reforms in China. Public Health 2011;125(1):6-8
   PubMed Web of Science ®Google Scholar
• Ling R, Liu F, Lu X, Wang W. Emerging issues in public health: A perspective on China’s healthcare system. Public Health 2011;125(1):9-4
   PubMed Web of Science ®Google Scholar
• Yu X, Li C, Shi Y, Yu M. Pharmaceutical supply chain in China: current issues and implications for health system reform. Health Policy 2010;97:8-15
   PubMed Web of Science ®Google Scholar
• National Health and Family Planning Commission of China: china Health Statistics Annuals 2011. Available from: http://wsb.moh.gov.cn/htmlfiles/zwgkzt/ptjnj/year2011/index2011.html [Last accessed December 2013]
   Google Scholar
• Mao W, Tang S, Chen W. Does perverse economic incentive lead to the irrational uses of medicines? Expert Rev Pharmacoecon Outcomes Res 2013;13(6):693-6
   PubMed Web of Science ®Google Scholar
• Sun Q, Santoro M, Meng Q, et al. Pharmaceutical policy in China. Health Aff 2008;27:1042-50
   PubMed Web of Science ®Google Scholar
• Tao T, Xu C, Hu M, et al. Analysis of Chinese pharmaceutical price policy from 1997 to 2011. Chin J Health Policy 2011;4:46-52
   Google Scholar
• Godman B, Bishop I, Finlayson A E, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2013;13(4):469-82
   PubMed Web of Science ®Google Scholar
• Yinan B. Radical treatment for healthcare. China Daily. Available from: www.chinadaily.com.cn/china/2010-09/16/content_11309825.htm [Last accessed January 2013]
   Google Scholar
• Chen Y, Schweitzer SO. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region. Value Health 2008;11:124-9
   PubMed Web of Science ®Google Scholar
• Wagstaff A, Lindelow M. Can insurance increase financial risk? The curious case of health insurance in China. J Health Econ 2008;27(4):990-1005
   PubMed Web of Science ®Google Scholar
• Jingang A. Which future for doctors in China? Lancet 2013;382:936-7
   PubMed Web of Science ®Google Scholar
• Meng Q, et al. The impact of China’s retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals. Health Policy Plan 2005;20:185-96
   PubMed Web of Science ®Google Scholar
• Liu L, Lu Z, Zhang X. Analysis of rational use of drugs in community health service facilities. Chinese Health Econ 2009;28(4):45-7
   Google Scholar
• Chinese Food and Drug Administration. Available from: http://app1.sfda.gov.cn/datasearch/face3/base.jsp?tableId=25&tableName=TABLE25&title=%E5%9B%BD%E4%BA%A7%E8%8D%AF%E5%93%81&bcId=124356560303886909015737447882 [Last accessed December 2013]
   Google Scholar
• Grimshaw J, Campbell M, Eccles M, et al. Experimental and quasi-experimental designs for evaluating guidelines implementation strategies. Fam Pract 2000;17:S11-16
   PubMed Web of Science ®Google Scholar
• Bucsics A, Godman B, Burkhardt T, et al. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2012;12(6):809-19
   PubMed Web of Science ®Google Scholar
• Simoens S, De Bruyn K, Miranda J, et al. Measures to enhance ARB prescribing efficiency in Belgium following generic losartan: impact and implications for the future. J Pharm Health Serv Res 2013;4:173-81
   Google Scholar
• Bennie M, Bishop I, Godman B, et al. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland? Qual Prim Care 2013;21:7-15
   PubMedGoogle Scholar
• Teng L, Xin HW, Blix HS, Tsutani K. Review of the use of defined daily dose concept in drug utilisation research in China. Pharmacoepidemiol Drug Saf 2012;21(10):1118-24
   PubMed Web of Science ®Google Scholar
• Vogler S, Zimmermann N, Leopold C, de Joncheere K. Pharmaceutical policies in European countries in response to the global financial crisis. South Med Review 2011;4(2):22-32
   Google Scholar
• Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France; implications for key stakeholder groups. Appl Health Econ Health Policy 2010;8:7-24
   PubMedGoogle Scholar
• WHO: guidelines for ATC classification and DDD assignment. In Oslo: WHO Collaborating Centre for Drug Statistics Methodology. Available from: www.whocc.no [Last accessed May 2014]
   Google Scholar
• WHO. Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330). Available from: www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug%20utilization%20research.pdf [Last accessed May 2014]
   Google Scholar
• Rønning M, Blix HS, Harbø BT, Strøm H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose – are drug utilisation data comparable? Eur J Clin Pharmacol 2000;56:723-7
   PubMed Web of Science ®Google Scholar
• Vlahovic-Palcevski V, Gantumur M, Radosevic N, et al. Coping with changes in Defined Daily Dose in longitudinal drug consumption databases. Pharm World Sci 2010;32:125-9
   PubMedGoogle Scholar
• Reynolds L, McKee M. Serve the people or close the sale? Profit-driven overuse of injections and infusions in China’s market-based healthcare system. Int J Health Plann Manage 2011;26:449-70
   PubMed Web of Science ®Google Scholar
• Björkhem-Bergman J, Andersen-Karlsson E, Laing R, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 2013;69(Suppl 1):S73-8
   PubMed Web of Science ®Google Scholar
• Karadis K, Tomson G, Wettermark B, et al. The establishment and expansion of an innovative centre for rational pharmacotherapy – determinants and challenges. Int J Health Plann Manage Published online in Wiley Online Library 2013;doi: 10.1002/hpm.2202. [Epub ahead of print]
   Web of Science ®Google Scholar
• Jian W-Y, Lu M, Cui T, Hu M. Evaluating performance of local case-mix system by international comparison: a case study in Beijing, China. Int J Health Plann Manage 2011;26:471-81
   PubMed Web of Science ®Google Scholar
• Yu S-Y, Yang B-M, Kim J-H. New anti-rebate legislation in South Korea. Appl Health Econ Health Policy 2013;11:311-18
   PubMedGoogle Scholar
• Roehr B. Drug companies will have to report all payments to US doctors from March 2014. BMJ 2013;346
   Google Scholar
• Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2008(4):CD003822
   Google Scholar
• Svanstrom H, Pasternak B, Hviid A. Association of treatment with losartan vs candesartan and mortality among Patients with heart failure. JAMA 2012;307:1506-12
   PubMed Web of Science ®Google Scholar
• Godman B, Bennie M, Bucsics A, et al. Variable approaches in Europe to the availability of generic losartan; implications for the future. Clin Therapeut 2013;35(8S):e36-7
   Google Scholar
• NICE updates its guidance on the management of hypertension. MeReC 10 October 2011. Available from: www.npc.nhs.uk/rapidreview/?p=4470 [Last accessed December 2013]
   Google Scholar
• Moon J, Godman B, Petzold M, et al. Different initiatives across Europe to enhance losartan utilisation post generics: impact and implications. Front Pharmacol 2014;5 (Article 219):1-10
   Web of Science ®Google Scholar